Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Bladder,
Kidney (Renal Cell),
Prostate,
Urologic
Phase I
Adults
Mol. targeted/Immunotherapy/Biologics
DCC-2812
Rini, Brian
International
Vanderbilt University
04-17-2026
Eligibility
18 Years and older
ALL
false
Inclusion Criteria:
Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Able to take oral medication
If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
Adequate organ function and electrolytes
Exclusion Criteria:
Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
Impaired cardiac function
Major surgery within 28 days of the first dose of study drug
Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Able to take oral medication
If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
Adequate organ function and electrolytes
Exclusion Criteria:
Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
Impaired cardiac function
Major surgery within 28 days of the first dose of study drug
